NCT06669572 2026-02-17Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial TreatmentUniversity of ChicagoPhase 2 Recruiting35 enrolled
NCT05273554 2026-01-12A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal AdenocarcinomaM.D. Anderson Cancer CenterPhase 1 Active not recruiting15 enrolled